<div><strong>Background: </strong>Canine appendicular osteosarcoma (OSA) is the most common bone malignancy in dogs.&nbsp;<br />
<br />
<strong>Methods:</strong> Spontaneous cases of canine OSA presented for three years were treated with different standard therapeutic protocols and compared with a novel plant formulations or nutraceuticals prepared from combination of turmeric, clove and olive oil. Different diagnostic modalities like survey and three view thoracic radiograph, abdominal ultrasonography (USG) with spectral Doppler USG, greyscale USG, strain elastography, fine needle aspiration cytology (FNAC), computed tomography and excisional biopsy were used to detect appendicular OSA and for staging of the primary bone tumor.<br />
<br />
<strong>Result:</strong> Canine bone tumor of appendicular OSA primarily affects large breed dogs with median age 10.32 years (range, 2.6-13 years) and median body weight 32.95 kg (range, 14-41 kg). Among four treatment groups, disease-free interval (DFI) and overall survival times were longer in groups of amputation followed by carboplatin as adjuvant chemotherapy (9 no.) than in groups with neoadjuvant chemotherapy with carboplatin followed by amputation (2 no.) and amputation along with nutraceuticals treatment (6 no.) and were shorter in the control group with amputation alone (6 no.). Herbal nutraceuticals can be included in the therapeutic regimen of canine osteosarcoma for increasing the overall survival time.&nbsp;</div>


<div>Comparative Evaluation of Nutraceuticals (<em>Curcuma longa</em> L., <em>Syzygium aromaticum </em>L. and <em>Olea europaea</em>) with Single-agent Carboplatin in the Management of Canine Appendicular Osteosarcoma</div>


Comparative Evaluation of Nutraceuticals (Curcuma longa L., Syzygium aromaticum L. and Olea europaea) with Single-agent Carboplatin in the Management of Canine Appendicular Osteosarcoma